Man Group
CLDX icon

Man Group’s Celldex Therapeutics CLDX Stock Holding History

Man Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-35,967
Closed -$1.22M – 2009
2024
Q3 		$1.22M Buy
+35,967
New +$1.37M ﹤0.01% 1452
2018
Q4 		– Sell
-733
Closed -$5K – 1939
2018
Q3 		$5K Hold
733
– – ﹤0.01% 2064
2018
Q2 		$6K Sell
733
-26,960
-97% -$360K ﹤0.01% 2089
2018
Q1 		$968K Buy
+27,693
New +$1.07M ﹤0.01% 1533

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Man Group's CLDX Position: Q4 2024 in Review

Man Group sold out of Celldex Therapeutics (CLDX) in Q4 2024, closing a stake of 35,967 shares — an estimated $1.22M sold.

Man Group first reported a position in CLDX in Q1 2018 and held it in 4 quarters. The position peaked at $1.22M in Q3 2024. 174 funds tracked by Wall St. Rank hold CLDX as of Q4 2024.

  • Man Group reported no remaining Celldex Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Man Group sold 35,967 Celldex Therapeutics shares in Q4 2024, an estimated $1.22M.
  • Man Group first reported a position in Celldex Therapeutics in Q1 2018 and held it in 4 quarters.
  • Man Group's Celldex Therapeutics position peaked at $1.22M in Q3 2024.
  • 174 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2024.

Based on Man Group's 13F filing for Q4 2024, filed 14 Feb 2025.